+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Autologous Cell Therapy Market - Growth, Trends, and Forecasts (2020 - 2025)

  • PDF Icon


  • 112 Pages
  • June 2020
  • Region: Global
  • Mordor Intelligence
  • ID: 4896189
UP TO OFF until Sep 30th 2023
The Autologous Cell Therapy market studied was anticipated to grow with a CAGR of 15.9%, during the forecast period. The major factors attributing to the growth of the autologous cell therapy market are the rising incidence of chronic diseases such as autoimmune diseases, cancer, blood disorder, and others. A rise in the population suffering from chronic diseases is also propelling the demand for market growth. In 2018, as per the AARDA (American Autoimmune Related Diseases Association) statistics, around 50 million Americans have an autoimmune disease, and this number is expected to rise in the future. As per the CDC (Centers for Disease Control and Prevention) estimates Sickel Cell Disease (SCD) affects around 100,000 Americans annually. And there are few more factors which are playing crucial roles in taking the autologous cell therapy market to the next level, among them one is on-going drug developments for new applications which are expected to further propel the growth of the autologous cell therapy market.

Key Market Trends

Bone Marrow Segment is Expected to Hold the Largest Market Share in the Autologous Cell Therapy Market
  • Bone marrow transplant is a technique for replacing damaged and destroyed cells with new stem cells in the bone marrow.
  • Bone marrow is the most commonly used for autologous cell therapy as it can benefit individuals with a range of cancer (malignant) and non-cancer (benign) diseases and will drive the market during the forecast period.
  • As per the statistics from Globocan 2018, worldwide 18,078,957 individuals have cancer. Asia remains the leading contributor in the rising incidence of cancer with a reported share of 48.4% followed by Europe, North and Latin America, Africa, and Oceania with a share of 23.4%, 13.2% and 7.8%, 5.8%, and 1.4% respectively.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall autologous cell therapy market, throughout the forecast period. This is owing to factors such as the rising incidence of chronic diseases such as cancer, blood disorder, autoimmune diseases, and other diseases and the availability of advanced healthcare infrastructure among the major factors. In North America region, the United States holds the largest market share owing to the factors such as increasing number of population suffering from cancer and other chronic diseases, along with the rising geriatric population and developments related to stem cell therapy and rising demand for biotechnological practices in the country, is anticipated to further drive the demand in this region.

Competitive Landscape

The autologous cell therapy market is moderately competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. And some prominent players are vigorously making acquisitions and joint ventures with the other companies to consolidate their market positions across the globe. Some of the companies which are currently dominating the market are Vericel Corporation, Pharmicell Co., Inc., Holostem Terapie Avanzate S.r.l., Lineage Cell Therapeutics, Inc., and Opexa Therapeutics.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incidence of Chronic Diseases
4.2.2 Emphasis Increasingly on Drug Development for New Applications
4.3 Market Restraints
4.3.1 Systemic immunological reactions possibility
4.3.2 Expensive practise, product and high capital investment
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Therapy
5.1.1 Autologous Stem Cell Therapy
5.1.2 Autologous Cellular Immunotherapies
5.2 By Application
5.2.1 Oncology
5.2.2 Musculoskeletal Disorder
5.2.3 Blood Disorder
5.2.4 Autoimmune Disease
5.2.5 Others
5.3 By Source
5.3.1 Bone Marrow
5.3.2 Epidermis
5.3.3 Others
5.4 By End User
5.4.1 Hospitals
5.4.2 Research Centers
5.4.3 Others
5.5 Geography
5.5.1 North America The United States Canada Mexico
5.5.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.5.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.5.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.5.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Vericel Corporation
6.1.2 Pharmicell Co., Inc.
6.1.3 Holostem Terapie Avanzate S.r.l.
6.1.4 Lineage Cell Therapeutics, Inc.
6.1.5 Opexa Therapeutics
6.1.6 BrainStorm Cell Therapeutics
6.1.7 Sangamo Therapeutics

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Vericel Corporation
  • Pharmicell Co., Inc.
  • Holostem Terapie Avanzate S.r.l.
  • Lineage Cell Therapeutics, Inc.
  • Opexa Therapeutics
  • BrainStorm Cell Therapeutics
  • Sangamo Therapeutics